Indeloxazine hydrochloride is a nootropic indicated for the treatment of senile dementia.
In animal models indeloxazine reportedly enhances brain energy metabolism and
monoamine content; its claimed protective effect on ischemia-induced amnesia is
supported by the prolonged step-through latency in passive avoidance tests.
After oral administration of indeloxazine hydrochloride
to rats, two conjugates, which are labile to a-
glucosidase hydrolysis but refractory to b-glucosidase,
are isolated from the urine and identified as a-D-
glucopyranosides of trans-4-(2-morpholinylmethoxy)-
1,2-indandiol and trans-6-[[(1,2-dihydroxy-4-
indanyl)oxy]-methyl]-3-morpholinone.
